A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine with or without Alum Adjuvant

Journal of Infectious Diseases

Volumn 215, Issue 1, 2017, Pages 24-33

  Langley, Joanne M ^a   Aggarwal, Naresh ^b   Toma, Azhar ^c   Halperin, Scott A ^a   McNeil, Shelly A ^a   Fissette, Laurence ^d   Dewé, Walthere ^d   Leyssen, Maarten ^d   Toussaint, Jean François ^d   Dieussaert, Ilse ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Aggarwal and Associates Limited   (Canada)

^c Manna Research   (Canada)

^d GSK   (Belgium)

Author keywords

maternal immunization; respiratory syncytial virus; vaccine; vaccine safety and immunogenicity

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS FUSION PROTEIN;

ADOLESCENT; ADULT; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; PHASE 1 CLINICAL TRIAL; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIROLOGY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUM COMPOUNDS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; HUMANS; MALE; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS; YOUNG ADULT;

EID: 85014554901     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw453     Document Type: Article

References (19)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-55.
2. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-36.
3. Langley JM, LeBlanc JC, Smith B, Wang EE. Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000. J Infect Dis 2003; 188:1764-7.
4. Englund JA. Maternal immunization-promises and concerns. Vaccine 2015; 33:6372-3.
5. World Health Organization (WHO). The Global Vaccine and Immunization Research Forum (GVIRF). 2015. http://www.who.int/immunization/research/forums-and-initiatives/gvirf/en/. Accessed 12 October 2015.
6. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21:3465-7.
7. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J 2008; 27:207-12.
8. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009; 123:398-403.
9. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 2013; 372:83-104.
10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7.
11. Magro M, Mas V, Chappell K, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 2012; 109:3089-94.
12. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592-8.
13. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol 2015; 35:30-8.
14. U.S. Department of Health and Human Services FaDA. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.Washington DC: Department of Health and Human Services, 2007.
15. Dreier JW, Andersen AM, Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. Pediatrics 2014; 133: e674-88.
16. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:110-5.
17. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21:3479-82.
18. PATH. RSV vaccine snapshot. 2015. http://sites.path.org/vaccinedevelopment/files/2015/07/RSV-snapshot-July2015.pdf. Accessed 12 October 2015.
19. Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2016; 213:411-22.